News | Focused Ultrasound Therapy | March 29, 2017

Multicenter retrospective analysis of 418 patients reveals survival rates above 70 percent across three subcategories

high-intensity focused ultrasound, HIFU, prostate tissue ablation, after radiotherapy, EDAP TMS SA, Ablatherm, British Journal of Urology International study

March 29, 2017 — EDAP TMS SA announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU (high-intensity focused ultrasound) for prostate tissue ablation in patients who had previously undergone radiotherapy treatment. The article concludes that HIFU should be considered as a valuable therapeutic option for carefully selected patients who failed a previous radiotherapy treatment. The article was published in the January 2017 edition of the British Journal of Urology International.

Authored by Pr. Sébastien Crouzet, M.D., Ph.D., from Edouard Herriot Hospital, Lyon, France, and co-authored by lead urologists from nine institutions across France, Germany, the U.K., Italy and the U.S., this retrospective analysis was designed to evaluate the outcomes of Ablatherm Robotic HIFU for the treatment of patients who had been previously treated with radiotherapy and were indicated for additional prostate tissue ablation. The results were compiled from the Ablatherm treatment registry (@-Registry), a multicenter secure online database for patients who have undergone prostate HIFU with Ablatherm. Inclusion criteria for the analysis were applied to the database, resulting in 418 patients with available data. Statistical models were applied to the data, using the longest available follow-up timepoint for each outcome and patient. Based on the Kaplan Meier survivorship analysis of this data, the rates of overall survival, cancer specific survival, and metastasis free survival at 7 years were 72, 82 and 81 percent, respectively.

Crouzet commented: "This is the largest series of salvage patients treated with HIFU and followed for data collection. The results are encouraging, and support the use of Ablatherm Robotic HIFU for these patients who are particularly fragile after the failure of their radiation treatment and are limited to minimally invasive treatment options. Patients who require additional treatment after a radiation therapy may benefit from prostate tissue ablation with HIFU."

For more information: www.onlinelibrary.wiley.com

Related Content

News | Women's Health

October 11, 2021 — Electrical engineering professor Magda El-Shenawee’s effort to develop a more accurate and less ...

Time October 11, 2021
arrow
News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
Feature | Radiation Therapy

September 28, 2021 — New research from Washington University School of Medicine in St. Louis suggests that radiation ...

Time September 28, 2021
arrow
News | Radiation Oncology

September 28, 2021 — The global radiotherapy devices market is expected to grow from $5.44 billion in 2020 to $5.848 ...

Time September 28, 2021
arrow
News | Prostate Cancer

September 24, 2021 — Scientists have identified two subtypes of metastatic prostate cancer that respond differently to ...

Time September 24, 2021
arrow
News | Radiation Therapy

September 24, 2021 — The "Global Surface Guided Radiation Therapy (SGRT) Devices Market, By Device Type (Portable v/s ...

Time September 24, 2021
arrow
News | Lung Imaging

September 23, 2021 — The National Cancer Institute announced that Virginia Commonwealth University Massey Cancer Center ...

Time September 23, 2021
arrow
News | Digital Pathology

September 22, 2021 — The U.S. Food and Drug Administration authorized marketing of software to assist medical ...

Time September 22, 2021
arrow
Subscribe Now